Literature DB >> 17914190

Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies.

Yukie Mitsuda1, Stephanie Planque, Mariko Hara, Robert Kyle, Hiroaki Taguchi, Yasuhiro Nishiyama, Sudhir Paul.   

Abstract

IgG class antibodies express catalytic activities rarely and at very low levels. Here, we studied polyclonal IgA and IgG preparations from healthy human sera and saliva for the ability to hydrolyze model peptidyl-aminomethylcoumarin (peptide-AMC) substrates. These substrates permit objective evaluation of the catalytic potential of the antibody classes with minimal effects of noncovalent interactions occurring at sites remote from the reaction center. The IgA preparations hydrolyzed Glu-Ala-Arg-AMC at rates 3-orders of magnitude greater than IgG preparations from the same individuals. The cleavage occurred preferentially on the C terminal side of a basic residue. The activity was confirmed using monoclonal IgAs isolated from patients with multiple myeloma. Active site-directed inhibitors of serine proteases inhibited the catalytic activity and were bound irreversibly by the IgA, suggesting the involvement of a serine protease-like mechanism similar to that utilized by previously described IgM antibodies. These observations suggest that mechanisms underlying B cell clonal selection favor the retention and improvement of catalytic activity in the IgA, but not the IgG compartment of the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914190     DOI: 10.1007/s12033-007-0003-7

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  37 in total

1.  Chronic glutamine supplementation increases nasal but not salivary IgA during 9 days of interval training.

Authors:  James W Krieger; Michelle Crowe; Sally E Blank
Journal:  J Appl Physiol (1985)       Date:  2004-04-23

Review 2.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

3.  High levels of catalytic antibodies correlate with favorable outcome in sepsis.

Authors:  Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri; David Hayon-Sonsino; Nithyananda Thorenoor; Julien Charpentier; Charles-Edouard Luyt; Jean-Paul Mira; Valakunja Nagaraja; Michel D Kazatchkine; Jean-François Dhainaut; Vincent O Mallet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

4.  DNA hydrolyzing autoantibodies.

Authors:  A M Shuster; G V Gololobov; O A Kvashuk; A E Bogomolova; I V Smirnov; A G Gabibov
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

Review 5.  Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases.

Authors:  G A Nevinsky; Valentina N Buneva
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

6.  Site-directed mutagenesis of proteolytic antibody light chain.

Authors:  Q S Gao; M Sun; A R Rees; S Paul
Journal:  J Mol Biol       Date:  1995-11-10       Impact factor: 5.469

7.  Hemostatic molecular markers in nephrotic syndrome.

Authors:  T Y Chen; C C Huang; C J Tsao
Journal:  Am J Hematol       Date:  1993-12       Impact factor: 10.047

8.  Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup.

Authors:  E H Sasso; G J Silverman; M Mannik
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

9.  Amidase activity of human Bence Jones proteins.

Authors:  K Matsuura; K Yamamoto; H Sinohara
Journal:  Biochem Biophys Res Commun       Date:  1994-10-14       Impact factor: 3.575

10.  Isotype choice for chimeric antibodies affects binding properties.

Authors:  M M Morelock; R Rothlein; S M Bright; M K Robinson; E T Graham; J P Sabo; R Owens; D J King; S H Norris; D S Scher
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

View more
  9 in total

Review 1.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

3.  Constant domain-regulated antibody catalysis.

Authors:  Gopal Sapparapu; Stephanie Planque; Yukie Mitsuda; Gary McLean; Yasuhiro Nishiyama; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

4.  Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.

Authors:  Stephanie Planque; Maria Salas; Yukie Mitsuda; Marcin Sienczyk; Miguel A Escobar; Jason P Mooney; Mary-Kate Morris; Yasuhiro Nishiyama; Dipanjan Ghosh; Amit Kumar; Feng Gao; Carl V Hanson; Sudhir Paul
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

5.  Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

Authors:  Ankit Mahendra; Ivan Peyron; Olivier Thaunat; Cécile Dollinger; Laurent Gilardin; Meenu Sharma; Bharath Wootla; Desirazu N Rao; Séverine Padiolleau-Lefevre; Didier Boquet; Abhijit More; Navin Varadarajan; Srini V Kaveri; Christophe Legendre; Sébastien Lacroix-Desmazes
Journal:  J Immunol       Date:  2016-04-11       Impact factor: 5.422

6.  Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Authors:  Stephanie A Planque; Yukie Mitsuda; Yasuhiro Nishiyama; Sangeeta Karle; Stephane Boivin; Maria Salas; Mary-Kate Morris; Mariko Hara; Guangling Liao; Richard J Massey; Carl V Hanson; Sudhir Paul
Journal:  J Immunol       Date:  2012-10-22       Impact factor: 5.422

7.  Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Mariko Hara; Sari Sonoda; Sarah K Murphy; Kenji Watanabe; Yukie Mitsuda; Eric L Brown; Richard J Massey; Stanley R Primmer; Brian O'Nuallain; Sudhir Paul
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

8.  IVIg treatment reduces catalytic antibody titers of renal transplanted patients.

Authors:  Ankit Mahendra; Ivan Peyron; Cécile Dollinger; Laurent Gilardin; Meenu Sharma; Bharath Wootla; Séverine Padiolleau-Lefevre; Alain Friboulet; Didier Boquet; Christophe Legendre; Srinivas V Kaveri; Olivier Thaunat; Sébastien Lacroix-Desmazes
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

9.  Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States.

Authors:  Evgeny A Ermakov; Georgy A Nevinsky; Valentina N Buneva
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.